For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Twist Bioscience Corp (NASDAQ: TWST) was $26.0 for the day, down -0.91% from the previous closing price of $26.24. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 1.28 million shares were traded. TWST stock price reached its highest trading level at $27.02 during the session, while it also had its lowest trading level at $25.86.
Ratios:
Our analysis of TWST’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 25 ’25 when WERNER ROBERT F. sold 853 shares for $27.69 per share. The transaction valued at 23,620 led to the insider holds 48,689 shares of the business.
Leproust Emily M. sold 2,716 shares of TWST for $70,518 on Aug 21 ’25. The Chief Executive Officer now owns 637,005 shares after completing the transaction at $25.96 per share. On Aug 21 ’25, another insider, WERNER ROBERT F., who serves as the Chief Accounting Officer of the company, sold 238 shares for $25.96 each. As a result, the insider received 6,179 and left with 49,542 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1569383424 and an Enterprise Value of 1411736064. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.33 while its Price-to-Book (P/B) ratio in mrq is 3.27. Its current Enterprise Value per Revenue stands at 3.897 whereas that against EBITDA is -11.817.
Stock Price History:
The Beta on a monthly basis for TWST is 2.39, which has changed by -0.3503248 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $24.28. The 50-Day Moving Average of the stock is -19.57%, while the 200-Day Moving Average is calculated to be -33.50%.
Shares Statistics:
TWST traded an average of 1.32M shares per day over the past three months and 1132080 shares per day over the past ten days. A total of 60.17M shares are outstanding, with a floating share count of 57.59M. Insiders hold about 4.59% of the company’s shares, while institutions hold 113.36% stake in the company. Shares short for TWST as of 1755216000 were 11008222 with a Short Ratio of 8.33, compared to 1752537600 on 10745056. Therefore, it implies a Short% of Shares Outstanding of 11008222 and a Short% of Float of 20.580000000000002.
Earnings Estimates
The stock of Twist Bioscience Corp (TWST) is currently in the spotlight, with 8.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.32 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$2.32 and -$2.32 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is -$1.28, with 9.0 analysts recommending between -$0.79 and -$1.76.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $97.96M to a low estimate of $96.73M. As of the current estimate, Twist Bioscience Corp’s year-ago sales were $84.71MFor the next quarter, 8 analysts are estimating revenue of $100.94M. There is a high estimate of $103.3M for the next quarter, whereas the lowest estimate is $99.04M.
A total of 8 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $375.52M, while the lowest revenue estimate was $374M, resulting in an average revenue estimate of $374.78M. In the same quarter a year ago, actual revenue was $312.97MBased on 8 analysts’ estimates, the company’s revenue will be $438.98M in the next fiscal year. The high estimate is $445.92M and the low estimate is $429.08M.
